CN118510803A - 对人和食蟹猴蛋白具有交叉反应性的抗cd3抗体 - Google Patents

对人和食蟹猴蛋白具有交叉反应性的抗cd3抗体 Download PDF

Info

Publication number
CN118510803A
CN118510803A CN202280082275.7A CN202280082275A CN118510803A CN 118510803 A CN118510803 A CN 118510803A CN 202280082275 A CN202280082275 A CN 202280082275A CN 118510803 A CN118510803 A CN 118510803A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
antibody
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280082275.7A
Other languages
English (en)
Chinese (zh)
Inventor
甄威
杨柳
方磊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lepu Biotechnology Co ltd
Original Assignee
Lepu Chuangyi Biotechnology Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lepu Chuangyi Biotechnology Shanghai Co ltd filed Critical Lepu Chuangyi Biotechnology Shanghai Co ltd
Publication of CN118510803A publication Critical patent/CN118510803A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202280082275.7A 2021-10-12 2022-10-12 对人和食蟹猴蛋白具有交叉反应性的抗cd3抗体 Pending CN118510803A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/123371 2021-10-12
CN2021123371 2021-10-12
PCT/CN2022/124968 WO2023061419A1 (en) 2021-10-12 2022-10-12 Anti-cd3 antibodies with cross-reactivity to human and cynomolgus proteins

Publications (1)

Publication Number Publication Date
CN118510803A true CN118510803A (zh) 2024-08-16

Family

ID=85987307

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280082275.7A Pending CN118510803A (zh) 2021-10-12 2022-10-12 对人和食蟹猴蛋白具有交叉反应性的抗cd3抗体

Country Status (5)

Country Link
US (1) US20250011427A1 (enExample)
EP (1) EP4416182A4 (enExample)
JP (1) JP2024537321A (enExample)
CN (1) CN118510803A (enExample)
WO (1) WO2023061419A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN122213233A (zh) * 2026-05-13 2026-06-16 赛业（苏州）生物科技有限公司 一种cd3抗体及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN122070305A (zh) * 2023-09-21 2026-05-19 艾科联生物科技(上海)有限公司 多特异性抗体及其用途
EP4791782A1 (en) * 2023-10-11 2026-08-19 Abany Biosciences (Hefei) Co. Ltd. An anti-cd3 activable antibody and the use thereof
WO2025103425A1 (en) * 2023-11-15 2025-05-22 Concept To Medicine Biotech Co., Ltd. Multispecific antibodies and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598732A (en) * 2009-10-27 2014-09-26 Amgen Res Munich Gmbh Dosage regimen for administering a cd19xcd3 bispecific antibody
AR103488A1 (es) * 2015-01-23 2017-05-10 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
HK1251480A1 (zh) * 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
CN118126180A (zh) * 2016-12-22 2024-06-04 第一三共株式会社 抗cd3抗体和包含所述抗体的分子
US11319371B2 (en) * 2017-06-05 2022-05-03 Numab Therapeutics AG Anti-CD3 antibodies
TW202010757A (zh) * 2018-04-11 2020-03-16 美商英伊布里克斯公司 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN122213233A (zh) * 2026-05-13 2026-06-16 赛业（苏州）生物科技有限公司 一种cd3抗体及其应用

Also Published As

Publication number Publication date
WO2023061419A1 (en) 2023-04-20
JP2024537321A (ja) 2024-10-10
US20250011427A1 (en) 2025-01-09
EP4416182A4 (en) 2025-09-17
EP4416182A1 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
KR102511268B1 (ko) Ig 및 itim 도메인을 갖는 t 세포 면역 수용체 (tigit)에 대한 항체 및 이것의 사용
KR102536145B1 (ko) 항-pd-1 항체 및 이의 용도
JP6728053B2 (ja) 抗ｍｃａｍ抗体及び関連する使用方法
JPWO2018147245A1 (ja) 抗ｇｐｒｃ５ｄ抗体及び該抗体を含む分子
CN118994403B (zh) 抗磷脂酰肌醇蛋白聚糖3抗体
US20250011427A1 (en) Anti-cd3 antibodies with cross-reactivity to human and cynomolgus proteins
WO2023056969A1 (en) Bispecific antibodies specifically binding to cd47 and cd20, and uses thereof
KR20220024211A (ko) 항-cd47 항체 및 그것의 사용
KR20230028708A (ko) 항-b7-h4/항-4-1bb 이중특이적 항체 및 이의 용도
CN118369341A (zh) 抗hla-g抗体
CN118556083A (zh) 具有改善的治疗指数的靶向cd3的t细胞衔接器
WO2023056970A1 (en) Bispecific antibodies specifically binding to cd47 and her2, and uses thereof
TW202600594A (zh) 結合構築體(一)
TWI869582B (zh) 抗ｃｄ４７抗體及其用途
HK40108102A (en) Cd3-targeting t-cell engagers with improved therapeutic index
HK40110049A (en) Anti-cd3 antibodies with cross-reactivity to human and cynomolgus proteins
WO2025061132A1 (en) Anti-dll3 antibodies and uses thereof
HK40113267A (en) Anti-glypican 3 antibodies
HK40085373A (en) Anti-cd47 antibody and uses thereof
HK40016537A (en) Anti-pd-1 antibodies and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40110049

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250613

Address after: 201112 Shanghai City Minhang District Pujiang Lianheng Road No. 651 Building 4 2nd Floor

Applicant after: Lepu Biotechnology Co.,Ltd.

Country or region after: China

Address before: 201203 Shanghai Pudong New Area Zhangheng Road 1077, Room B207 Dade Chuangtong

Applicant before: Lepu Chuangyi Biotechnology (Shanghai) Co.,Ltd.

Country or region before: China